Nitric Oxide Production in MELAS Syndrome
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Introduction
Baylor College of Medicine and Texas Children's Hospital are recruiting individuals with MELAS syndrome for a clinical study. Mitochondria are cell structures that provide energy for most cells of the body. MELAS syndrome is a mitochondrial disease; patients with this disease have muscle weakness and often develop brain strokes, where blood does not flow normally to different parts of the brain. It is believed that these strokes could be due to decreased production of nitric oxide, a naturally occurring compound important for normal blood vessel function. Nitric oxide is made from other common compounds arginine and citrulline that are normally found in our bodies.
What is the purpose of this study? The purpose of this study is to measure nitric oxide in individuals with MELAS syndrome and see if giving arginine or citrulline will increase the formation of nitric oxide. Nitric oxide is thought to be helpful in improving blood vessel function and preventing strokes. Therefore, if arginine and/or citrulline are shown to increase the formation of nitric oxide, they could be used to prevent or treat the strokes in patients with MELAS syndrome.
What does the study involve? Individuals with MELAS syndrome will be admitted twice to the General Clinical Research Center (GCRC) at Texas Children's Hospital. Each time they will stay for five days, during which a special diet will be provided. Nitric oxide production will be measured by a safe stable isotopes infusion technique that involves placing small tubes in veins (IV catheter), blood sampling, and injecting a harmless stable isotope. Stable isotopes are forms of normal compounds that can be measured very accurately but not radioactive and there are no known risks to giving them; they are already part of your body in small amounts.
During the first admission nitric oxide levels will be measured, then arginine supplementation will be provided for 48 hours, after which nitric oxide levels will be re-measured to determine the effect of arginine supplementation. During the second admission, the effect of citrulline supplementation will be measured.
Who can participate in the study? Adults or children affected with MELAS syndrome and carrying the DNA change that causes the condition (3243 A>G mutation) can participate. Adults without MELAS disease will be recruited to participate as control subjects.
How to get more information? Subjects interested in participation or getting more information can contact Dr. Ayman El-Hattab at email: elhattab@bcm.edu, office phone: 832-822-4289, cell phone: 646-660-5666, or pager: 832-824-7243 (5523).
| Condition | Intervention |
|---|---|
|
MELAS Syndrome |
Dietary Supplement: Arginine and citrulline supplementations |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | ARGININE FLUX AND NITRIC OXIDE PRODUCTION IN PATIENTS WITH MELAS SYNDROME AND THE EFFECT OF ARGININE AND CITRULLINE SUPPLEMENTATION |
- Change in nitric oxide production [ Time Frame: Nitric oxide production will be measured at baseline before supplementation and after 48 hours of arginine or citrulline supplementation ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 10 |
| Study Start Date: | July 2009 |
| Estimated Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
-
Dietary Supplement: Arginine and citrulline supplementations
Eligibility| Ages Eligible for Study: | 3 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age from 3 - 65 years
- Clinical diagnosis of MELAS syndrome
- Carrying the m.3243A>G mutation
Exclusion Criteria:
- Having acute or chronic disease or physical disability that will interfere with the ability to undergo the study procedures
- Being pregnant
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01339494
| Contact: Ayman W El-Hattab, M.D. | 832-822-4289 | elhattab@bcm.edu |
| United States, Texas | |
| Texas Children's Hospital | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Ayman W El-Hattab, MD 832-822-4289 elhattab@bcm.edu | |
| Principal Investigator: Fernando Scaglia, MD | |
| Principal Investigator: | Fernando Scaglia, M.D. | Baylor College of Medicine |
More Information
No publications provided
| Responsible Party: | Fernando Scaglia, Baylor College of Medicine |
| ClinicalTrials.gov Identifier: | NCT01339494 History of Changes |
| Other Study ID Numbers: | H-24783 |
| Study First Received: | April 19, 2011 |
| Last Updated: | April 19, 2011 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Mitochondrial Diseases Mitochondrial Encephalomyopathies Mitochondrial Myopathies Muscular Diseases MELAS Syndrome Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Cardiovascular Diseases Central Nervous System Diseases |
Cerebral Small Vessel Diseases Cerebrovascular Disorders Genetic Diseases, Inborn Metabolic Diseases Metabolism, Inborn Errors Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on March 03, 2015